Cost and value in liver disease guidelines: 2011-2022.
Elizabeth S AbyAlyson KaplanNneka N UferePublished in: Hepatology communications (2023)
Forty-five CGDs were identified. Eighty of 1334 guidance statements were C/V statements (6%). Only 1.1% reported patient-level costs and none reported out-of-pocket costs. Despite the increased importance of incorporating cost and value into care, the proportion of C/V statements in CGDs related to liver disease is low.